Short answer
ACCURAY INC (ARAY) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $105M (down 7.4% year over year) with net income of −$12M.
Q1 2026 key financials · XBRL
- Revenue
- $105M
- −7.4% YoY · +2.5% QoQ
- Net income
- −$12M
- −810.2% YoY · +14.3% QoQ
- Operating margin
- -8.7%
- Gross margin
- 24.1%
- EPS (diluted)
- −$0.09
- −350.0% YoY · +25.0% QoQ
Source: XBRL data from the ACCURAY INC (ARAY) Q1 2026 10-Q on SEC EDGAR. USD.
ACCURAY INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $104.8M, down 7% YoY from $113.2M, driven by lower China and Asia Pacific shipments
- Gross margin 24.1% vs 27.9% YoY, pressured by $3.2M higher net parts consumption and logistics and duties costs
- Best region Americas revenue $24.5M, up 20% YoY; worst Asia Pacific revenue $9.3M, down 38%
- Operating expenses $34.4M, 33% of revenue vs 27% YoY, including $6.5M restructuring charges
- Outlook headwinds: delayed Middle East shipments, China pressure, tariffs, supply-chain costs and inflation through fiscal year 2026
Risk Factors
- Newly highlighted 2026 risk: tariffs on U.S.-China trade expected to reduce China product sales and increase costs
- Regulatory compliance risk: material internal-control weaknesses remain through March 31, 2026, impairing timely, accurate financial reporting
- Near-term market risk: U.S. customer financing delays and reduced radiotherapy-equipment budgets expected to pressure revenue through fiscal 2026
- Financial risk: $18.0 million of 3.75% Convertible Senior 2026 Notes mature June 1, 2026
- Leverage risk: $156.5 million outstanding under Credit Facilities, secured by substantially all assets, with covenant-default foreclosure exposure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ACCURAY INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.